title: Activity of FCE 20696, a new synthetic immunomodulator, in models of viral and bacterial pathology.
abstract: The dibenzopyran derivative FCE 20696 is an immunomodulator which protects mice infected with several viral agents and with Mycobacterium tuberculosis. The compound is able to decrease the severity of the lung lesions caused by influenza virus infection. Doses ranging from 12.5 to 100 mg/kg are effective even after a single administration. Activity is demonstrated by intraperitoneal, subcutaneous and oral administration of the drug. In systemic infection with herpes simplex virus type 1, the 100 mg/kg dosage, administered subcutaneously, is able to increase both the percentage and the mean survival time of mice. To have effect by oral administration it is necessary to give the compound twice in the day. Moreover, some activity has also been observed in mice infected by M. tuberculosis, when the compound is administered orally at doses of 1-2.5 mg/kg twice weekly for 5 weeks, during the course of the disease.
authors: Department of Infectious Diseases, Farmitalia Carlo Erba Research Center, Milano, Italy.
authors: M A
authors: MA
authors: Verini
authors: D
authors: D
authors: Ungheri
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006561:Herpes Simplex / Q000188:drug therapy; D007372:Interferons / Q000096:biosynthesis; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy; D014376:Tuberculosis / Q000188:drug therapy
chemical_list: C051455:6H,6-(2-(dimethylamino)ethoxycarbonyl)dibenzo(b,d)pyran; D000276:Adjuvants, Immunologic; D001578:Benzopyrans; D007372:Interferons